In our laboratory at Biocant Park in Cantanhede, Portugal our Colleagues Artur Rodrigues and Vanessa F. work on CHO4Tx®, our brand-new high performance CHO 🧪 transfection system.
🧐 Is your objective to improve efficiency in the rapid production of protein candidates for R&D in therapeutics or diagnostics?
👉 We at Magellan Biologics & Consulting proudly support the scientificcommunity in their R&D projects through our CHO4Tx® product portfolio that allows in-house, fast, easy and efficient transient proteinexpression in CHO cells and through personalized advices and consultancies.
A novel drug produced in CHO cells has recently been approved by the FDA
Tislelizumab-jsgr is a PD-1 blocking antibody indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic
29 March 2024
